Clinical Value of a 51-Neuroendocrine Tumor-Specific Gene Signature (NETest 2.0) for Management of Pancreatic and Small Bowel Neuroendocrine Tumors: A Prospective Study in a Consecutive Cohort of 82 Patients Considered for Surgery
Frilling A, Clift A, Spalding D, Drymousis P, von Roon A, Goldin R, et al.
Ann Surg Open. 2026;7(3):e700.

